The addition of rituximab (R) to CHOP (cyclophosphamide, doxorubicin, vincristine,
prednisone) chemotherapy was a milestone in the development of front‐line therapy for …

Incorporation of the anti-CD20 monoclonal antibody rituximab into front-line regimens to
treat diffuse large B cell lymphoma (DLBCL) has resulted in improved survival. Despite this …

Rituximab‐containing salvage chemotherapy followed by high‐dose therapy and
autologous stem cell transplant (ASCT) in chemosensitive patients remains the standard of …

Background: Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and
prednisone (CHOP) significantly prolonged event-free survival in first-line chemotherapy for …

Background We have investigated if rituximab-based salvage regimens improve response
rates and survival of patients with diffuse large B-cell lymphoma (DLBCL) relapsing after an …

Rituximab administered as induction or maintenance therapy in combination with
cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly prolonged …

The use of highly effective rituximab‐containing therapy for treating diffuse large B‐cell
lymphoma (DLBCL) makes it more difficult to salvage relapsed or refractory patients …

Salvage chemotherapy followed by high-dose therapy and autologous stem cell
transplantation is the standard of treatment for chemosensitive relapses in diffuse large B …

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin's lymphoma in the
developed world. 1 Anthracycline based combination chemotherapy regimens became …

The poor prognosis for patients with diffuse large B cell lymphoma (DLBCL) who relapse
within 1 year of initial diagnosis after first-line rituximab-based chemo-immunotherapy has …